154 related articles for article (PubMed ID: 32470302)
1. Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
Ernst JT; Thompson PA; Nilewski C; Sprengeler PA; Sperry S; Packard G; Michels T; Xiang A; Tran C; Wegerski CJ; Eam B; Young NP; Fish S; Chen J; Howard H; Staunton J; Molter J; Clarine J; Nevarez A; Chiang GG; Appleman JR; Webster KR; Reich SH
J Med Chem; 2020 Jun; 63(11):5879-5955. PubMed ID: 32470302
[TBL] [Abstract][Full Text] [Related]
2. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.
Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH
Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608
[TBL] [Abstract][Full Text] [Related]
3. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract][Full Text] [Related]
4. Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors.
Nilewski C; Michels TD; Xiang AX; Packard GK; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Ernst JT; Reich SH
Org Lett; 2020 Aug; 22(16):6257-6261. PubMed ID: 32806219
[TBL] [Abstract][Full Text] [Related]
5. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract][Full Text] [Related]
6. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
Iwasaki S; Floor SN; Ingolia NT
Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
[TBL] [Abstract][Full Text] [Related]
7. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.
Tillotson J; Kedzior M; Guimarães L; Ross AB; Peters TL; Ambrose AJ; Schmidlin CJ; Zhang DD; Costa-Lotufo LV; Rodríguez AD; Schatz JH; Chapman E
Bioorg Med Chem Lett; 2017 Sep; 27(17):4082-4085. PubMed ID: 28757063
[TBL] [Abstract][Full Text] [Related]
8. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
Iwasaki S; Iwasaki W; Takahashi M; Sakamoto A; Watanabe C; Shichino Y; Floor SN; Fujiwara K; Mito M; Dodo K; Sodeoka M; Imataka H; Honma T; Fukuzawa K; Ito T; Ingolia NT
Mol Cell; 2019 Feb; 73(4):738-748.e9. PubMed ID: 30595437
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
[TBL] [Abstract][Full Text] [Related]
11. eIF4B stimulates eIF4A ATPase and unwinding activities by direct interaction through its 7-repeats region.
Andreou AZ; Harms U; Klostermeier D
RNA Biol; 2017 Jan; 14(1):113-123. PubMed ID: 27858515
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
[TBL] [Abstract][Full Text] [Related]
13. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis.
Oguro A; Ohtsu T; Svitkin YV; Sonenberg N; Nakamura Y
RNA; 2003 Apr; 9(4):394-407. PubMed ID: 12649492
[TBL] [Abstract][Full Text] [Related]
14. Targeting the eIF4A RNA helicase as an anti-neoplastic approach.
Chu J; Pelletier J
Biochim Biophys Acta; 2015 Jul; 1849(7):781-91. PubMed ID: 25234619
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI.
Zakowicz H; Yang HS; Stark C; Wlodawer A; Laronde-Leblanc N; Colburn NH
RNA; 2005 Mar; 11(3):261-74. PubMed ID: 15661843
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
17. eIF4B stimulates translation of long mRNAs with structured 5' UTRs and low closed-loop potential but weak dependence on eIF4G.
Sen ND; Zhou F; Harris MS; Ingolia NT; Hinnebusch AG
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10464-72. PubMed ID: 27601676
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products.
Shen L; Pelletier J
Nat Prod Rep; 2020 May; 37(5):609-616. PubMed ID: 31782447
[TBL] [Abstract][Full Text] [Related]
19. Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: negation of domain-linker regulation of activity.
Low WK; Dang Y; Bhat S; Romo D; Liu JO
Chem Biol; 2007 Jun; 14(6):715-27. PubMed ID: 17584618
[TBL] [Abstract][Full Text] [Related]
20. Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with
Peters TL; Tillotson J; Yeomans AM; Wilmore S; Lemm E; Jiménez-Romero C; Amador LA; Li L; Amin AD; Pongtornpipat P; Zerio CJ; Ambrose AJ; Paine-Murrieta G; Greninger P; Vega F; Benes CH; Packham G; Rodríguez AD; Chapman E; Schatz JH
Clin Cancer Res; 2018 Sep; 24(17):4256-4270. PubMed ID: 29844128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
